BG104528A - Method and means for the treatment of impotence - Google Patents

Method and means for the treatment of impotence

Info

Publication number: BG104528A
Authority: BG; Bulgaria
Prior art keywords: treatment; impotence; compound selected; relates; cgmp
Prior art date: 1997-12-16

Application number

BG104528A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michael G. Wyllie

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-16

Filing date

2000-06-13

Publication date

2001-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22090927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104528(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-13 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2001-02-28 Publication of BG104528A publication Critical patent/BG104528A/xx

Links

201000001881 impotence Diseases 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
239000000674 adrenergic antagonist Substances 0.000 abstract 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 abstract 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229960003310 sildenafil Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG104528A 1997-12-16 2000-06-13 Method and means for the treatment of impotence BG104528A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6974197P	1997-12-16	1997-12-16
PCT/IB1998/001723 WO1999030697A2 (en)	1997-12-16	1998-10-29	Combination effective for the treatment of impotence

Publications (1)

Publication Number	Publication Date
BG104528A true BG104528A (en)	2001-02-28

Family

ID=22090927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104528A BG104528A (en)	1997-12-16	2000-06-13	Method and means for the treatment of impotence

Country Status (37)

Country	Link
EP (1)	EP1037616B1 (cs)
JP (2)	JP2002508315A (cs)
KR (1)	KR20010033092A (cs)
CN (1)	CN1282248A (cs)
AP (1)	AP915A (cs)
AR (1)	AR016433A1 (cs)
AT (1)	ATE318602T1 (cs)
AU (1)	AU759825B2 (cs)
BG (1)	BG104528A (cs)
BR (1)	BR9813699A (cs)
CA (1)	CA2314993A1 (cs)
CO (1)	CO4810381A1 (cs)
CZ (1)	CZ20002199A3 (cs)
DE (1)	DE69833671T2 (cs)
DZ (1)	DZ2675A1 (cs)
EA (1)	EA200000526A1 (cs)
ES (1)	ES2258300T3 (cs)
GT (1)	GT199800177A (cs)
HN (1)	HN1998000174A (cs)
HR (1)	HRP20000407A2 (cs)
HU (1)	HUP0100705A3 (cs)
IL (1)	IL136515A0 (cs)
IS (1)	IS5504A (cs)
MA (1)	MA26586A1 (cs)
NO (1)	NO20003065L (cs)
NZ (1)	NZ504487A (cs)
OA (1)	OA11423A (cs)
PA (1)	PA8462801A1 (cs)
PE (1)	PE20000011A1 (cs)
PL (1)	PL341575A1 (cs)
SK (1)	SK8782000A3 (cs)
TN (1)	TNSN98227A1 (cs)
TR (1)	TR200001733T2 (cs)
UY (1)	UY25300A1 (cs)
WO (1)	WO1999030697A2 (cs)
YU (1)	YU33700A (cs)
ZA (1)	ZA9811507B (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6469065B1 (en)	1996-02-02	2002-10-22	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en)	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19844162A1 (de) *	1998-09-25	2000-03-30	Udo Dunzendorfer	Medikamentenkombinationen zur Therapie der erektilen Dysfunktion
AU3724400A (en) *	1999-03-08	2000-09-28	Merck & Co., Inc.	Methods and compositions for treating erectile dysfunction
US7235625B2 (en) *	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
ATE399554T1 (de) *	1999-08-03	2008-07-15	Lilly Icos Llc	Pharmazeutische zusammensetzung enthaltend tadalafil
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2000270300A1 (en) *	2000-09-13	2002-03-26	Isis Innovation Limited	Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1333824B1 (en) *	2000-11-17	2005-09-07	Warner-Lambert Company LLC	Treatment of sexual dysfunction with bombesin receptor antagonists
US20030114469A1 (en) *	2001-09-27	2003-06-19	Cohen David Saul	Combinations
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
GB0225908D0 (en) *	2002-11-06	2002-12-11	Pfizer Ltd	Treatment of female sexual dysfunction
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
CA2451267A1 (en)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
AP2007004047A0 (en)	2005-01-20	2007-06-30	Pfizer Ltd	Substituted triazole derivatives as oxtocin antagonists
US8506934B2 (en)	2005-04-29	2013-08-13	Robert I. Henkin	Methods for detection of biological substances
US8067433B2 (en)	2005-11-09	2011-11-29	Zalicus Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008095136A2 (en)	2007-01-31	2008-08-07	Henkin Robert I	Methods for detection of biological substances
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
CN101781302B (zh) *	2009-05-31	2013-07-10	段波	一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
WO2014055801A1 (en)	2012-10-05	2014-04-10	Henkin Robert I	Phosphodiesterase inhibitors for treating taste and smell disorders
WO2015126944A1 (en)	2014-02-18	2015-08-27	Henkin Robert I	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US11590209B2 (en)	2020-01-21	2023-02-28	Palatin Technologies, Inc.	Use of bremelanotide in patients with controlled hypertension
CN115485027A (zh)	2020-03-24	2022-12-16	思瑞诺医疗有限公司	冠状病毒感染引起的化学感觉功能障碍的治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA878182B (en) *	1986-11-05	1988-05-02	Merrell Dow Pharmaceuticals Inc.	Enhancement of prazosin
FR2649613B1 (fr) *	1989-07-11	1991-09-27	Virag Ronald	Medicament vaso-actif
US5242391A (en) *	1990-04-25	1993-09-07	Alza Corporation	Urethral insert for treatment of erectile dysfunction
DK0459666T3 (da) *	1990-05-31	1994-12-05	Pfizer	Lægemidler mod impotens
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
GB9523752D0 (en) *	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations

1998
- 1998-10-29 BR BR9813699-2A patent/BR9813699A/pt not_active Application Discontinuation
- 1998-10-29 NZ NZ504487A patent/NZ504487A/xx unknown
- 1998-10-29 DE DE69833671T patent/DE69833671T2/de not_active Expired - Fee Related
- 1998-10-29 EP EP98947741A patent/EP1037616B1/en not_active Revoked
- 1998-10-29 CN CN98812331A patent/CN1282248A/zh active Pending
- 1998-10-29 KR KR1020007006455A patent/KR20010033092A/ko not_active Ceased
- 1998-10-29 CA CA002314993A patent/CA2314993A1/en not_active Abandoned
- 1998-10-29 YU YU33700A patent/YU33700A/sh unknown
- 1998-10-29 HU HU0100705A patent/HUP0100705A3/hu unknown
- 1998-10-29 TR TR2000/01733T patent/TR200001733T2/xx unknown
- 1998-10-29 HR HR20000407A patent/HRP20000407A2/hr not_active Application Discontinuation
- 1998-10-29 IL IL13651598A patent/IL136515A0/xx unknown
- 1998-10-29 SK SK878-2000A patent/SK8782000A3/sk unknown
- 1998-10-29 AT AT98947741T patent/ATE318602T1/de not_active IP Right Cessation
- 1998-10-29 AU AU94558/98A patent/AU759825B2/en not_active Ceased
- 1998-10-29 CZ CZ20002199A patent/CZ20002199A3/cs unknown
- 1998-10-29 JP JP2000538680A patent/JP2002508315A/ja active Pending
- 1998-10-29 EA EA200000526A patent/EA200000526A1/ru unknown
- 1998-10-29 ES ES98947741T patent/ES2258300T3/es not_active Expired - Lifetime
- 1998-10-29 WO PCT/IB1998/001723 patent/WO1999030697A2/en not_active Ceased
- 1998-10-29 PL PL98341575A patent/PL341575A1/xx unknown
- 1998-11-09 GT GT199800177A patent/GT199800177A/es unknown
- 1998-11-10 PA PA19988462801A patent/PA8462801A1/es unknown
- 1998-11-11 HN HN1998000174A patent/HN1998000174A/es unknown
- 1998-11-30 CO CO98070722A patent/CO4810381A1/es unknown
- 1998-12-10 AP APAP/P/1998/001414A patent/AP915A/en active
- 1998-12-11 PE PE1998001206A patent/PE20000011A1/es not_active Application Discontinuation
- 1998-12-14 UY UY25300A patent/UY25300A1/es not_active Application Discontinuation
- 1998-12-15 MA MA25396A patent/MA26586A1/fr unknown
- 1998-12-15 AR ARP980106360A patent/AR016433A1/es unknown
- 1998-12-15 TN TNTNSN98227A patent/TNSN98227A1/fr unknown
- 1998-12-15 DZ DZ980285A patent/DZ2675A1/xx active
- 1998-12-15 ZA ZA9811507A patent/ZA9811507B/xx unknown
2000
- 2000-05-19 IS IS5504A patent/IS5504A/is unknown
- 2000-06-13 BG BG104528A patent/BG104528A/xx unknown
- 2000-06-15 OA OA1200000169A patent/OA11423A/en unknown
- 2000-06-15 NO NO20003065A patent/NO20003065L/no not_active Application Discontinuation
2007
- 2007-08-20 JP JP2007213745A patent/JP2007332156A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AP9801414A0 (en)	1998-12-31
GT199800177A (es)	2000-05-02
CN1282248A (zh)	2001-01-31
CA2314993A1 (en)	1999-06-24
DE69833671T2 (de)	2006-11-30
TR200001733T2 (tr)	2000-11-21
HRP20000407A2 (en)	2000-10-31
JP2007332156A (ja)	2007-12-27
NZ504487A (en)	2002-11-26
ES2258300T3 (es)	2006-08-16
IL136515A0 (en)	2001-06-14
EA200000526A1 (ru)	2000-12-25
KR20010033092A (ko)	2001-04-25
AU9455898A (en)	1999-07-05
CO4810381A1 (es)	1999-06-30
NO20003065D0 (no)	2000-06-15
PA8462801A1 (es)	2000-05-24
YU33700A (sh)	2004-05-12
HN1998000174A (es)	1999-01-08
EP1037616A2 (en)	2000-09-27
HUP0100705A2 (hu)	2001-08-28
WO1999030697A2 (en)	1999-06-24
WO1999030697A3 (en)	1999-08-26
IS5504A (is)	2000-05-19
ZA9811507B (en)	2000-06-19
TNSN98227A1 (fr)	2005-03-15
AU759825B2 (en)	2003-05-01
AR016433A1 (es)	2001-07-04
DZ2675A1 (fr)	2003-03-29
PE20000011A1 (es)	2000-01-18
UY25300A1 (es)	2000-12-29
ATE318602T1 (de)	2006-03-15
SK8782000A3 (en)	2002-03-05
EP1037616B1 (en)	2006-03-01
JP2002508315A (ja)	2002-03-19
HUP0100705A3 (en)	2001-12-28
NO20003065L (no)	2000-08-15
AP915A (en)	2000-12-18
BR9813699A (pt)	2000-10-10
OA11423A (en)	2004-04-21
PL341575A1 (en)	2001-04-23
MA26586A1 (fr)	2004-12-20
DE69833671D1 (de)	2006-04-27
CZ20002199A3 (cs)	2001-10-17

Publication	Publication Date	Title
WO1999030697A3 (en)	1999-08-26	Combination effective for the treatment of impotence
BG104406A (en)	2001-08-31	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EP1090644A3 (en)	2004-01-14	Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator
ZA200600475B (en)	2007-04-25	Pyrimidine-2,4-dione derivatives as gonadotripin-releasing hormone receptor antagonists
AU2001244192A1 (en)	2001-09-24	Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction
MY134783A (en)	2007-12-31	Rho-kinase inhibitors
MY142915A (en)	2011-01-31	Rho-kinase inhibitors
CY1107747T1 (el)	2013-04-18	Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
AP2001002125A0 (en)	2001-04-04	Controlled-rease pharmaceutical formulations.
WO2002060392A3 (en)	2003-09-25	Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
NZ334954A (en)	2000-08-25	Substituted heterocycles as anti-tumor agents
ATE348101T1 (de)	2007-01-15	Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
MXPA04000531A (es)	2004-05-04	Acilsemicarbazidas como inhibidores de cinasa dependiente de ciclina utiles como agentes anti-cancer y anti-proliferativos.
DK1109814T3 (da)	2004-08-02	5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
SI1673354T1 (sl)	2009-10-31	Arilindenopiridini in arilindenopirimidini in njihova uporaba kot antagonisti adenozinskih A2a-receptorjev
EP1400522A4 (en)	2006-04-05	NEW COMPOUNDS FOR THE TREATMENT OF IMPUSE
PT1642576E (pt)	2009-05-21	Utilização de derivados de pirrole para combate da ansiedade
YU60803A (sh)	2006-05-25	Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
ATE247656T1 (de)	2003-09-15	Pyrazolo(1,5-a)triazine als crf antagonisten
EP1057829A4 (en)	1999-12-10	Condensed pyrimidine derivatives and pharmaceutical compositions containing them
ECSP982789A (es)	1999-04-21	Combinacion eficaz para el tratamiento de la impotencia
MY139385A (en)	2009-09-30	Benzimidazoles that are useful in treating sexual dysfunction